Bluebird bio to cut 25% of workforce as part of restructuring
Sept 24 (Reuters) - Gene therapy maker bluebird bio BLUE.O said on Tuesday it would cut 25% of its workforce as part of a restructuring program for cost reduction. (Reporting by Christy Santhosh; Editing by Shilpi Majumdar) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on bluebird bio
See all newsBrief: Bluebird Bio Announces Completion Of Acquisition By Carlyle And SK Capital
Brief: Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
Brief: Carlyle, SK Capital Partners And Bluebird Bio Provide Updated Tender Instructions
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Robinhood, Oklo, Chimera Investment